Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology Index Fund (NASD: IBB) where we have detected an approximate $48.0 million dollar inflow — that’s a 1.9% increase week over week in outstanding units (from 15,900,000 to 16,200,000). Among the largest underlying components of IBB, in trading today Amgen Inc (NASD: AMGN) is up about 0.8%, Celgene Corp. (NASD: CELG) is up about 1.5%, and Alexion Pharmaceuticals Inc. (NASD: ALXN) is up by about 1.2%. For a complete list of holdings, visit the IBB Holdings page ยป …read more
Source: FULL ARTICLE at Forbes Markets
Tag Archives: CELG
Get An Even Better Deal On CELG Than Director Drake Did
There’s an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on February 4, Celgene Corp.’s Director, Rodman L. Drake, invested $39,399.04 into 400 shares of CELG, for a cost per share of $98.50. Bargain hunters tend to pay particular attention to insider buys like this one, because presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money. …read more
Source: FULL ARTICLE at Forbes Markets
Analyst Moves: CELG, BSX
By MarketNewsVideo Celgene (CELG) was upgraded by Bank of America/Merrill Lynch (BAC) to buy from neutral with a price target of $115, as the firm believes that the company can experience compound annual growth of 25% during the next five years.
Source: FULL ARTICLE at Forbes Markets